2021.Nov.08.

A subsidiary of Inscoby Co., Ltd., a KOSPI-listed company, and the Korea Atomic Energy Research Institute established Insgen Co., Ltd., a joint research corporation for industry-academic research through the intermediation of SYP technology transfer.

SYP Co., Ltd. conducted demand discovery of Inscoby, technology matching of nuclear power, patent and market research on the technology, and BM advancement, and established a bio-accelerator individual investment association to conduct seed investment with Korea Science and Technology Holdings (KST). 

Related press release :  

▶ Money Today : https://news.mt.co.kr/mtview.php?no=2021110109471262724

Apimez, a subsidiary of Inscovie (130-3.6%, up KRW 3,455) will launch a research institute company with the Korea Atomic Energy Research Institute and expand its competitiveness in the natural product-based pharmaceutical and health food market. Inscoby announced on the 1st that Insgen, a subsidiary of Apimez, signed a technology transfer contract from the Korea Atomic Energy Research Institute for "technology to develop diabetes and anticancer drugs using bio-food and pharmaceutical materials."

Apimez established InsGen INC, a subsidiary of natural product health functional foods and new drug development, and Insgen received technology from the Korea Atomic Energy Research Institute. In order to promote future research results and commercialization, Korea Science and Technology Holdings, which was invested by 17 government-funded research institutes, will also invest additionally in Insgen.

The technology transferred is a technology to develop diabetes and anticancer drugs using natural products such as bio and food and medicine. The technology was developed by the Korea Atomic Energy Research Institute through its own R&D project and national R&D support project. It has already completed two international SCI-level papers and three patent registrations, and animal experiments have proven that it has excellent anti-diabetes (multi-targetable) and more than 95% anti-cancer effects.

In addition to entering the natural product health functional food market based on technology, Insgen plans to develop exclusive new natural product drugs through follow-up clinical trials. It is expected that it will be able to enter the diabetes treatment and anticancer drug market based on the development of high value-added new drugs in the future.

"Apimez, which has experience in researching and developing apitoxin, Korea's No. 1 natural drug, is expected to be of great help in the development of new drugs and health functional foods based on DDS (drug delivery system) technology accumulated by its subsidiary Ingen."

"Inscovie's bio affiliates are achieving tangible results in each bio sector, so we will be able to grow into a bio-medi-tech platform in earnest," he added.